Deepen school enterprise cooperation! Suzhou University - Wisdom Therapy RNA Drug Collaborative Innovation Center Established!

Recently, the "Suzhou University Wisdom Therapy RNA Drug Collaborative Innovation Center" jointly established by Suzhou University and Suzhou Wisdom Therapy Biomedical Technology Co., Ltd. was officially established.

After the establishment of the center

It will greatly promote the in-depth cooperation between industry, academia and research in the field of nucleic acid drugs, fully integrate the advantages of Soochow University in basic research and technology development, as well as the advantages of Huihui Biotechnology in production, operation and industrialization, jointly build a nucleic acid drug application innovation center, serve the development of China's nucleic acid drug industry, and further establish Suzhou's leading position in the development of nucleic acid drugs.

Wisdom Therapy Biology
Established in May 2021, headquartered in the 2.5 Industrial Park of the park, it is a high-tech enterprise with research and industrialization technology for nucleic acid (RNA) drugs.

The company focuses on the research and development of innovative RNA drugs, with an intelligent RNA sequence design library and IVT synthesis platform, a delivery system platform with independent intellectual property rights, and a superfluid nanodrug production process platform. It is committed to building an internationally leading RNA pharmaceutical company.

For many years, the park has regarded the biopharmaceutical industry as the "number one industry" leading future development, focusing on gathering innovative resources and elements to seize the high ground of industrial innovation.
The industrial development has maintained a high-speed growth trend for consecutive years

In the past three years, the number of innovative enterprises cultivated in the park, the scale of national high-level talents, the approval of clinical approvals for Class 1.1 biopharmaceuticals, the total production capacity of biopharmaceuticals, and the total financing amount of enterprises have all accounted for more than 20% of the national total.

In March of this year, the park was approved to build a national biopharmaceutical technology innovation center; In October, the Biotechnology Center of the Ministry of Science and Technology released the latest ranking of national biopharmaceutical industry parks, ranking first in the comprehensive competitiveness of the parks as well as in the three special competitiveness of industry, talent, and technology.

Next, the park will further strengthen the core position of innovation in development.

Strive to create the optimal innovation atmosphere, promote the layout of innovation resources, continuously amplify the strategic role of universities in the innovation chain, and actively promote cooperation between universities and enterprises.

Make every effort to build a world-class biopharmaceutical industry highland with international competitiveness.